Expanded Access to Telisotuzumab Vedotin
- Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Registration Number
- NCT04830202
- Lead Sponsor
- AbbVie
- Brief Summary
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Telisotuzumab vedotin prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- AVAILABLE
- Sex
- Not specified
- Target Recruitment
- Not specified
- The participant must not be eligible for a telisotuzumab vedotin clinical trial.
Not provided
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (9)
Oncology & Hematology Specialist /ID# 248083
🇺🇸Mountain Lakes, New Jersey, United States
Sutter Medical Group /ID# 254816
🇺🇸Sacramento, California, United States
Western Heamatology and Oncology Clinics /ID# 243364
🇦🇺West Perth, Western Australia, Australia
Asklepios Fachkliniken Muenchen-Gauting /ID# 259196
🇩🇪Gauting, Germany
University Hospital Cologne /ID# 254773
🇩🇪Cologne, Germany
The Chaim Sheba Medical Center /ID# 256530
🇮🇱Ramat Gan, Tel-Aviv, Israel
Shaare Zedek Medical Center /ID# 252374
🇮🇱Jerusalem, Israel
Rabin Medical Center /ID# 228611
🇮🇱Petakh Tikva, Israel
Hong Kong United Oncology Centre /ID# 241857
ðŸ‡ðŸ‡°Yau Ma Tei, Hong Kong